Halozyme Therapeutics Inc (HALO)

[maumar]

Genmab Commences New Arbitration Under License Agreement With Janssen

Interesting development:

"The tribunal based its ruling on the finding that DARZALEX FASPRO constitutes a new licensed product under the license agreement.

In this new arbitration, Genmab is consequently seeking an award of $405 million plus interest in accrued milestone payments for DARZALEX FASPRO and a declaration that it is entitled to a new 13-year royalty term from the date of DARZALEX FASPRO’s first commercial sale."

https://www.globenewswire.com/news-release/2022/06/09/2460165/0/en/Genmab-Commences-New-Arbitration-Under-License-Agreement-With-Janssen.html